이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
Il-yang Pharm’s leukemia drug proven effective against Parkinson`s disease
- Collected
- 2016.08.18
- Distributed
- 2016.08.18
- Source
- Go Direct
Il-yang Pharm said it recently filed a patent on its leukemia drug radotinib as it demonstrated better penetration of the brain blood barrier compared with compounds developed by global pharmaceutical companies. The research was conducted together with the Johns Hopkins team led by Dr. Ko Han-seok, a professor at Johns Hopkins School of Medicine.
The non-clinical study showed radotinib lowered the cohesion of alpha-synuclein that can cause Parkinson`s. The compound also demonstrated its ability to inhibit the activation of c-ABL proteins known to cause the disease.
Previous studies showed the inhibition of c-ABL can stop or delay the progression of the disease.
The discovery is based on drug repositioning, which aims to identify new indications for existing drugs. Radotinib for Parkinson`s can be quickly commercialized as its safety for humans are already proven as a leukemia drug.
By Lee Dong-in
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]